Loading…
Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures
Background Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the efficacy of the therapy for failures to prior direct-acting antiviral (DAA) regimens in real-world practice is not well known. Meth...
Saved in:
| Published in: | Journal of gastroenterology 2019-03, Vol.54 (3), p.291-296 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c463t-75e5a5e5f1a86dce18ab5206d8369ee5f7828e58a5c22f88e884141559a8dff23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c463t-75e5a5e5f1a86dce18ab5206d8369ee5f7828e58a5c22f88e884141559a8dff23 |
| container_end_page | 296 |
| container_issue | 3 |
| container_start_page | 291 |
| container_title | Journal of gastroenterology |
| container_volume | 54 |
| creator | Osawa, Mitsutaka Imamura, Michio Teraoka, Yuji Uchida, Takuro Morio, Kei Fujino, Hatsue Nakahara, Takashi Ono, Atsushi Murakami, Eisuke Kawaoka, Tomokazu Miki, Daiki Tsuge, Masataka Hiramatsu, Akira Aikata, Hiroshi Hayes, C. Nelson Chayama, Kazuaki |
| description | Background
Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the efficacy of the therapy for failures to prior direct-acting antiviral (DAA) regimens in real-world practice is not well known.
Methods
Thirty patients infected with HCV genotype 1b, 2a, 2b, or 3a who failed to respond during prior DAA therapies were treated with GLE/PIB for 12 weeks. HCV NS3 and NS5A drug resistance-associated variants (RAVs) were determined by direct sequencing.
Results
Twenty-eight out of 30 patients (93.3%) achieved SVR12 by GLE/PIB treatment. SVR12 rates were similar between patients with and without advanced liver fibrosis (94.7% and 91.0%, respectively). All 9 patients with genotype 2a, 2b, or 3a HCV infection achieved SVR12. However, two genotype 1b HCV-infected patients who failed previous daclatasvir plus asunaprevir treatment experienced HCV relapse after the end of GLE/PIB treatment. Direct sequence analysis showed the presence of NS3-D168E plus NS5A-L31I/P58S/Y93H RAVs in one patient and NS5A-L31F/P32del RAVs in another patient before GLE/PIB treatment. In the former patient, NS3-D168E plus NS5A-L31I/P58S/Y93H RAVs persisted, and additional NS5A-L28M/V75A variants emerged after HCV relapse.
Conclusions
GLE/PIB treatment for HCV-infected patients who did not respond to prior DAA treatments was highly effective regardless of liver fibrosis stage. However, some genotype 1b HCV-infected patients, especially those with NS5A-P32del, may have low susceptibility to the treatment. |
| doi_str_mv | 10.1007/s00535-018-1520-9 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2121558619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714583072</galeid><sourcerecordid>A714583072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-75e5a5e5f1a86dce18ab5206d8369ee5f7828e58a5c22f88e884141559a8dff23</originalsourceid><addsrcrecordid>eNp1UduKFDEQDaK44-oH-CIBn7Pm0ulOPy6DN1gQRJ9DTboyk6Wn0yZpl_kGf9q0s7oISigSTp1zUsUh5KXgV4Lz7k3mXCvNuDBMaMlZ_4hsRFMR3Uv5mGx43zRMiK65IM9yvuVcKK7NU3KhuFIN79sN-fEZYWR3MY0DRe-DA3ei0dP9iA7mhN9DovO4ZDqHXcKpQF4RHxN1hxSn4OgBZyihhEy3dH1VEr0L5UB_qWOVDiGhKwxcCdOewlRC9YCRlgMmmE_UQxiXhPk5eeJhzPji_r4kX9-9_bL9wG4-vf-4vb5hrmlVYZ1GDbW8ANMODoWBXd2-HYxqe6x4Z6RBbUA7Kb0xaEwjGqF1D2bwXqpL8vrsO6f4bcFc7G1c0lS_tFLISjSt6B9YexjRhsnHksAdQ3b2uhONNop3q9fVP1j1DHgMLk7oQ8X_EoizwKWYc0Jv5xSOkE5WcLumas-p2pqqXVO16yiv7gdedkcc_ih-x1gJ8kzItTXtMT1s9H_Xn53rrio</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2121558619</pqid></control><display><type>article</type><title>Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures</title><source>Springer Nature</source><creator>Osawa, Mitsutaka ; Imamura, Michio ; Teraoka, Yuji ; Uchida, Takuro ; Morio, Kei ; Fujino, Hatsue ; Nakahara, Takashi ; Ono, Atsushi ; Murakami, Eisuke ; Kawaoka, Tomokazu ; Miki, Daiki ; Tsuge, Masataka ; Hiramatsu, Akira ; Aikata, Hiroshi ; Hayes, C. Nelson ; Chayama, Kazuaki</creator><creatorcontrib>Osawa, Mitsutaka ; Imamura, Michio ; Teraoka, Yuji ; Uchida, Takuro ; Morio, Kei ; Fujino, Hatsue ; Nakahara, Takashi ; Ono, Atsushi ; Murakami, Eisuke ; Kawaoka, Tomokazu ; Miki, Daiki ; Tsuge, Masataka ; Hiramatsu, Akira ; Aikata, Hiroshi ; Hayes, C. Nelson ; Chayama, Kazuaki ; Hiroshima Liver Study Group ; Hiroshima Liver Study Group</creatorcontrib><description>Background
Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the efficacy of the therapy for failures to prior direct-acting antiviral (DAA) regimens in real-world practice is not well known.
Methods
Thirty patients infected with HCV genotype 1b, 2a, 2b, or 3a who failed to respond during prior DAA therapies were treated with GLE/PIB for 12 weeks. HCV NS3 and NS5A drug resistance-associated variants (RAVs) were determined by direct sequencing.
Results
Twenty-eight out of 30 patients (93.3%) achieved SVR12 by GLE/PIB treatment. SVR12 rates were similar between patients with and without advanced liver fibrosis (94.7% and 91.0%, respectively). All 9 patients with genotype 2a, 2b, or 3a HCV infection achieved SVR12. However, two genotype 1b HCV-infected patients who failed previous daclatasvir plus asunaprevir treatment experienced HCV relapse after the end of GLE/PIB treatment. Direct sequence analysis showed the presence of NS3-D168E plus NS5A-L31I/P58S/Y93H RAVs in one patient and NS5A-L31F/P32del RAVs in another patient before GLE/PIB treatment. In the former patient, NS3-D168E plus NS5A-L31I/P58S/Y93H RAVs persisted, and additional NS5A-L28M/V75A variants emerged after HCV relapse.
Conclusions
GLE/PIB treatment for HCV-infected patients who did not respond to prior DAA treatments was highly effective regardless of liver fibrosis stage. However, some genotype 1b HCV-infected patients, especially those with NS5A-P32del, may have low susceptibility to the treatment.</description><identifier>ISSN: 0944-1174</identifier><identifier>EISSN: 1435-5922</identifier><identifier>DOI: 10.1007/s00535-018-1520-9</identifier><identifier>PMID: 30334096</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Abdominal Surgery ; Aged ; Aged, 80 and over ; Analysis ; Antiviral agents ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Antiviral drugs ; Benzimidazoles - therapeutic use ; Biliary Tract ; Care and treatment ; Colorectal Surgery ; Drug resistance ; Female ; Fibrosis ; Gastroenterology ; Genotype ; Genotype & phenotype ; Genotypes ; Health aspects ; Hepacivirus - genetics ; Hepatitis ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Hepatology ; Humans ; Interferon ; Japan ; Liver ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Original Article—Liver ; Pancreas ; Patients ; Quinoxalines - adverse effects ; Quinoxalines - therapeutic use ; Recurrence ; Retreatment ; Sulfonamides - adverse effects ; Sulfonamides - therapeutic use ; Surgical Oncology ; Treatment Failure ; Treatment Outcome</subject><ispartof>Journal of gastroenterology, 2019-03, Vol.54 (3), p.291-296</ispartof><rights>Japanese Society of Gastroenterology 2018</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Journal of Gastroenterology is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-75e5a5e5f1a86dce18ab5206d8369ee5f7828e58a5c22f88e884141559a8dff23</citedby><cites>FETCH-LOGICAL-c463t-75e5a5e5f1a86dce18ab5206d8369ee5f7828e58a5c22f88e884141559a8dff23</cites><orcidid>0000-0003-4123-6290</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30334096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Osawa, Mitsutaka</creatorcontrib><creatorcontrib>Imamura, Michio</creatorcontrib><creatorcontrib>Teraoka, Yuji</creatorcontrib><creatorcontrib>Uchida, Takuro</creatorcontrib><creatorcontrib>Morio, Kei</creatorcontrib><creatorcontrib>Fujino, Hatsue</creatorcontrib><creatorcontrib>Nakahara, Takashi</creatorcontrib><creatorcontrib>Ono, Atsushi</creatorcontrib><creatorcontrib>Murakami, Eisuke</creatorcontrib><creatorcontrib>Kawaoka, Tomokazu</creatorcontrib><creatorcontrib>Miki, Daiki</creatorcontrib><creatorcontrib>Tsuge, Masataka</creatorcontrib><creatorcontrib>Hiramatsu, Akira</creatorcontrib><creatorcontrib>Aikata, Hiroshi</creatorcontrib><creatorcontrib>Hayes, C. Nelson</creatorcontrib><creatorcontrib>Chayama, Kazuaki</creatorcontrib><creatorcontrib>Hiroshima Liver Study Group</creatorcontrib><creatorcontrib>Hiroshima Liver Study Group</creatorcontrib><title>Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures</title><title>Journal of gastroenterology</title><addtitle>J Gastroenterol</addtitle><addtitle>J Gastroenterol</addtitle><description>Background
Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the efficacy of the therapy for failures to prior direct-acting antiviral (DAA) regimens in real-world practice is not well known.
Methods
Thirty patients infected with HCV genotype 1b, 2a, 2b, or 3a who failed to respond during prior DAA therapies were treated with GLE/PIB for 12 weeks. HCV NS3 and NS5A drug resistance-associated variants (RAVs) were determined by direct sequencing.
Results
Twenty-eight out of 30 patients (93.3%) achieved SVR12 by GLE/PIB treatment. SVR12 rates were similar between patients with and without advanced liver fibrosis (94.7% and 91.0%, respectively). All 9 patients with genotype 2a, 2b, or 3a HCV infection achieved SVR12. However, two genotype 1b HCV-infected patients who failed previous daclatasvir plus asunaprevir treatment experienced HCV relapse after the end of GLE/PIB treatment. Direct sequence analysis showed the presence of NS3-D168E plus NS5A-L31I/P58S/Y93H RAVs in one patient and NS5A-L31F/P32del RAVs in another patient before GLE/PIB treatment. In the former patient, NS3-D168E plus NS5A-L31I/P58S/Y93H RAVs persisted, and additional NS5A-L28M/V75A variants emerged after HCV relapse.
Conclusions
GLE/PIB treatment for HCV-infected patients who did not respond to prior DAA treatments was highly effective regardless of liver fibrosis stage. However, some genotype 1b HCV-infected patients, especially those with NS5A-P32del, may have low susceptibility to the treatment.</description><subject>Abdominal Surgery</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antiviral drugs</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Biliary Tract</subject><subject>Care and treatment</subject><subject>Colorectal Surgery</subject><subject>Drug resistance</subject><subject>Female</subject><subject>Fibrosis</subject><subject>Gastroenterology</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Health aspects</subject><subject>Hepacivirus - genetics</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Interferon</subject><subject>Japan</subject><subject>Liver</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Original Article—Liver</subject><subject>Pancreas</subject><subject>Patients</subject><subject>Quinoxalines - adverse effects</subject><subject>Quinoxalines - therapeutic use</subject><subject>Recurrence</subject><subject>Retreatment</subject><subject>Sulfonamides - adverse effects</subject><subject>Sulfonamides - therapeutic use</subject><subject>Surgical Oncology</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><issn>0944-1174</issn><issn>1435-5922</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1UduKFDEQDaK44-oH-CIBn7Pm0ulOPy6DN1gQRJ9DTboyk6Wn0yZpl_kGf9q0s7oISigSTp1zUsUh5KXgV4Lz7k3mXCvNuDBMaMlZ_4hsRFMR3Uv5mGx43zRMiK65IM9yvuVcKK7NU3KhuFIN79sN-fEZYWR3MY0DRe-DA3ei0dP9iA7mhN9DovO4ZDqHXcKpQF4RHxN1hxSn4OgBZyihhEy3dH1VEr0L5UB_qWOVDiGhKwxcCdOewlRC9YCRlgMmmE_UQxiXhPk5eeJhzPji_r4kX9-9_bL9wG4-vf-4vb5hrmlVYZ1GDbW8ANMODoWBXd2-HYxqe6x4Z6RBbUA7Kb0xaEwjGqF1D2bwXqpL8vrsO6f4bcFc7G1c0lS_tFLISjSt6B9YexjRhsnHksAdQ3b2uhONNop3q9fVP1j1DHgMLk7oQ8X_EoizwKWYc0Jv5xSOkE5WcLumas-p2pqqXVO16yiv7gdedkcc_ih-x1gJ8kzItTXtMT1s9H_Xn53rrio</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Osawa, Mitsutaka</creator><creator>Imamura, Michio</creator><creator>Teraoka, Yuji</creator><creator>Uchida, Takuro</creator><creator>Morio, Kei</creator><creator>Fujino, Hatsue</creator><creator>Nakahara, Takashi</creator><creator>Ono, Atsushi</creator><creator>Murakami, Eisuke</creator><creator>Kawaoka, Tomokazu</creator><creator>Miki, Daiki</creator><creator>Tsuge, Masataka</creator><creator>Hiramatsu, Akira</creator><creator>Aikata, Hiroshi</creator><creator>Hayes, C. Nelson</creator><creator>Chayama, Kazuaki</creator><general>Springer Japan</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><orcidid>https://orcid.org/0000-0003-4123-6290</orcidid></search><sort><creationdate>20190301</creationdate><title>Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures</title><author>Osawa, Mitsutaka ; Imamura, Michio ; Teraoka, Yuji ; Uchida, Takuro ; Morio, Kei ; Fujino, Hatsue ; Nakahara, Takashi ; Ono, Atsushi ; Murakami, Eisuke ; Kawaoka, Tomokazu ; Miki, Daiki ; Tsuge, Masataka ; Hiramatsu, Akira ; Aikata, Hiroshi ; Hayes, C. Nelson ; Chayama, Kazuaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-75e5a5e5f1a86dce18ab5206d8369ee5f7828e58a5c22f88e884141559a8dff23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Abdominal Surgery</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antiviral drugs</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Biliary Tract</topic><topic>Care and treatment</topic><topic>Colorectal Surgery</topic><topic>Drug resistance</topic><topic>Female</topic><topic>Fibrosis</topic><topic>Gastroenterology</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Health aspects</topic><topic>Hepacivirus - genetics</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Interferon</topic><topic>Japan</topic><topic>Liver</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Original Article—Liver</topic><topic>Pancreas</topic><topic>Patients</topic><topic>Quinoxalines - adverse effects</topic><topic>Quinoxalines - therapeutic use</topic><topic>Recurrence</topic><topic>Retreatment</topic><topic>Sulfonamides - adverse effects</topic><topic>Sulfonamides - therapeutic use</topic><topic>Surgical Oncology</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osawa, Mitsutaka</creatorcontrib><creatorcontrib>Imamura, Michio</creatorcontrib><creatorcontrib>Teraoka, Yuji</creatorcontrib><creatorcontrib>Uchida, Takuro</creatorcontrib><creatorcontrib>Morio, Kei</creatorcontrib><creatorcontrib>Fujino, Hatsue</creatorcontrib><creatorcontrib>Nakahara, Takashi</creatorcontrib><creatorcontrib>Ono, Atsushi</creatorcontrib><creatorcontrib>Murakami, Eisuke</creatorcontrib><creatorcontrib>Kawaoka, Tomokazu</creatorcontrib><creatorcontrib>Miki, Daiki</creatorcontrib><creatorcontrib>Tsuge, Masataka</creatorcontrib><creatorcontrib>Hiramatsu, Akira</creatorcontrib><creatorcontrib>Aikata, Hiroshi</creatorcontrib><creatorcontrib>Hayes, C. Nelson</creatorcontrib><creatorcontrib>Chayama, Kazuaki</creatorcontrib><creatorcontrib>Hiroshima Liver Study Group</creatorcontrib><creatorcontrib>Hiroshima Liver Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osawa, Mitsutaka</au><au>Imamura, Michio</au><au>Teraoka, Yuji</au><au>Uchida, Takuro</au><au>Morio, Kei</au><au>Fujino, Hatsue</au><au>Nakahara, Takashi</au><au>Ono, Atsushi</au><au>Murakami, Eisuke</au><au>Kawaoka, Tomokazu</au><au>Miki, Daiki</au><au>Tsuge, Masataka</au><au>Hiramatsu, Akira</au><au>Aikata, Hiroshi</au><au>Hayes, C. Nelson</au><au>Chayama, Kazuaki</au><aucorp>Hiroshima Liver Study Group</aucorp><aucorp>Hiroshima Liver Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures</atitle><jtitle>Journal of gastroenterology</jtitle><stitle>J Gastroenterol</stitle><addtitle>J Gastroenterol</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>54</volume><issue>3</issue><spage>291</spage><epage>296</epage><pages>291-296</pages><issn>0944-1174</issn><eissn>1435-5922</eissn><abstract>Background
Combination therapy with glecaprevir (GLE) and pibrentasvir (PIB) has high efficacy for pan-genotypic hepatitis C virus (HCV)-infected patients. However, the efficacy of the therapy for failures to prior direct-acting antiviral (DAA) regimens in real-world practice is not well known.
Methods
Thirty patients infected with HCV genotype 1b, 2a, 2b, or 3a who failed to respond during prior DAA therapies were treated with GLE/PIB for 12 weeks. HCV NS3 and NS5A drug resistance-associated variants (RAVs) were determined by direct sequencing.
Results
Twenty-eight out of 30 patients (93.3%) achieved SVR12 by GLE/PIB treatment. SVR12 rates were similar between patients with and without advanced liver fibrosis (94.7% and 91.0%, respectively). All 9 patients with genotype 2a, 2b, or 3a HCV infection achieved SVR12. However, two genotype 1b HCV-infected patients who failed previous daclatasvir plus asunaprevir treatment experienced HCV relapse after the end of GLE/PIB treatment. Direct sequence analysis showed the presence of NS3-D168E plus NS5A-L31I/P58S/Y93H RAVs in one patient and NS5A-L31F/P32del RAVs in another patient before GLE/PIB treatment. In the former patient, NS3-D168E plus NS5A-L31I/P58S/Y93H RAVs persisted, and additional NS5A-L28M/V75A variants emerged after HCV relapse.
Conclusions
GLE/PIB treatment for HCV-infected patients who did not respond to prior DAA treatments was highly effective regardless of liver fibrosis stage. However, some genotype 1b HCV-infected patients, especially those with NS5A-P32del, may have low susceptibility to the treatment.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>30334096</pmid><doi>10.1007/s00535-018-1520-9</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4123-6290</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0944-1174 |
| ispartof | Journal of gastroenterology, 2019-03, Vol.54 (3), p.291-296 |
| issn | 0944-1174 1435-5922 |
| language | eng |
| recordid | cdi_proquest_journals_2121558619 |
| source | Springer Nature |
| subjects | Abdominal Surgery Aged Aged, 80 and over Analysis Antiviral agents Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Benzimidazoles - therapeutic use Biliary Tract Care and treatment Colorectal Surgery Drug resistance Female Fibrosis Gastroenterology Genotype Genotype & phenotype Genotypes Health aspects Hepacivirus - genetics Hepatitis Hepatitis C Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Hepatology Humans Interferon Japan Liver Male Medicine Medicine & Public Health Middle Aged Original Article—Liver Pancreas Patients Quinoxalines - adverse effects Quinoxalines - therapeutic use Recurrence Retreatment Sulfonamides - adverse effects Sulfonamides - therapeutic use Surgical Oncology Treatment Failure Treatment Outcome |
| title | Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A13%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real-world%20efficacy%20of%20glecaprevir%20plus%20pibrentasvir%20for%20chronic%20hepatitis%20C%20patient%20with%20previous%20direct-acting%20antiviral%20therapy%20failures&rft.jtitle=Journal%20of%20gastroenterology&rft.au=Osawa,%20Mitsutaka&rft.aucorp=Hiroshima%20Liver%20Study%20Group&rft.date=2019-03-01&rft.volume=54&rft.issue=3&rft.spage=291&rft.epage=296&rft.pages=291-296&rft.issn=0944-1174&rft.eissn=1435-5922&rft_id=info:doi/10.1007/s00535-018-1520-9&rft_dat=%3Cgale_proqu%3EA714583072%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c463t-75e5a5e5f1a86dce18ab5206d8369ee5f7828e58a5c22f88e884141559a8dff23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2121558619&rft_id=info:pmid/30334096&rft_galeid=A714583072&rfr_iscdi=true |